AS PRFoods Unaudited Consolidated Interim Report 3d Quarter and 9 months 2022/23
May 31 2023 - 4:56PM
AS PRFoods Unaudited Consolidated Interim Report 3d Quarter and 9
months 2022/23
Consolidated Unaudited Interim Report of AS PRFoods for
the 3rd quarter and
9 months of
2022/2023
financial year
PRFoods continues to operate now as Estonian-British group,
having two productions facilities in Estonia and United Kingdom
respectively. Fish farming operations are taking place only in
Estonia, with further capacity expansions planned. Q3 and 9 months
results show that downsizing operations was risky but proven right,
as our profitability has substantially improved. EBITDA from
operations improved from -1,1 meur year ago to 0,04 meur. Operating
results was near zero when last year it was still -1,4 meur. We
finished quarter with small profit compared to -4,5 meur loss last
year (due to divestments). On 9 months basis our EBITDA from
operations improved from -2,3 meur to 200,000 eur positive result,
, while our sales were down 57%. Gross profit improved by 23% in
absolute terms, which is very remarkable result. We finished 9
months with 800,000 eur profit compared to -6,6 million lass last
year (incl one -off effect of divestments)While our products are in
strong demand, the overall price increases have negative effect on
purchase frequency. High inflation and high food prices persist,
making consumption growth unlikely. Also high leverage of the group
straddles the company with extreme cash flow management challenges.
We believe with new farming licences we can re-establish PRFoods as
regional leader in fish farming and processing. 2024 we see
significant growth in sales to Finland and elsewhere in the region.
Challenges remain, as for entire food processing sector, but I am
very pleased with personal commitment and professionalism in our
operating companies, John Ross Jr. and Saare Kala. Their effort has
put the company on new lease of life.
KEY RATIOS
INCOME STATEMENT
mln EURunless indicated otherwise |
3Q 2022/2023 |
2021/2022 |
3Q 2021/2022 |
2020/2021 |
Sales |
3,7 |
42,1 |
7,4 |
58,7 |
Gross profit |
1,1 |
3,1 |
-0,3 |
5 |
EBITDA from operations |
0,0 |
-1,7 |
-1,1 |
-1,2 |
EBITDA |
0,2 |
-2,1 |
-0,9 |
-1,3 |
EBIT |
-0,1 |
-4,2 |
-1,4 |
-3,9 |
EBT |
0,1 |
-8,2 |
-4,5 |
-5 |
Net profit (loss) |
0,1 |
-8,2 |
-4,5 |
-5,2 |
Gross margin |
28,7% |
7,4% |
-4,3% |
8,50% |
Operational EBITDA margin |
10% |
-4,1% |
-15,5% |
-2,1% |
EBITDA margin |
5,7% |
-5,1% |
-12,2% |
-2,1% |
EBIT margin |
-1,9% |
-9,9% |
-19,2% |
-6,6% |
EBT margin |
2,7% |
-19,5% |
-63,7% |
-8,5% |
Net margin |
2,8% |
-19,4% |
-61,1% |
-8,8% |
Operating expense ratio |
-37,1% |
-17,1% |
-15,6% |
16,1% |
BALANCE SHEET
mln EURunless indicated otherwise |
31.03.2023 |
30.06.2022 |
31.03.2022 |
30.06.2021 |
Net debt |
16,58 |
24,7 |
23,9 |
20,9 |
Equity |
7,8 |
8,1 |
10,1 |
15,8 |
Working capital |
0,8 |
-3,2 |
-2,9 |
-2,9 |
Assets |
29,8 |
38,9 |
40 |
55,3 |
Liquidity ratio |
1,0x |
0,7x |
1,0x |
0,9x |
Equity ratio |
26,0% |
20,7% |
25,3% |
28,6% |
Gearing ratio |
68,1% |
75,4% |
70,2 |
56,9% |
Debt to total assets |
0,8x |
0,8x |
0,8x |
0,7x |
Net debt to operating EBITDA |
21,4x |
-14,5x |
21,4x |
-16,9x |
ROE |
1,3% |
-68,5% |
-34,8% |
-28,7% |
ROA |
0,3% |
-17,3% |
-9,4% |
-9,1% |
Consolidated Statement of Financial
Position
EUR '000 |
31.03.2023 |
31.03.2022 |
30.06.2022 |
ASSETS |
|
|
|
Cash and cash equivalents |
457 |
119 |
110 |
Receivables and prepayments |
3 093 |
3 669 |
2 567 |
Inventories |
1 785 |
2 661 |
2 196 |
Biological assets |
- |
2 313 |
3 003 |
Total current assets |
5 336 |
8 762 |
7 876 |
|
|
|
|
Deferred tax assets |
- |
97 |
93 |
Long-term financial investments |
304 |
230 |
229 |
Tangible assets |
6 766 |
9 017 |
8 882 |
Intangible assets |
17 401 |
21 942 |
21 837 |
Total non-current assets |
24 471 |
31 286 |
31 041 |
TOTAL ASSETS |
29 806 |
40 048 |
38 917 |
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
Interest-bearing liabilities |
1 450 |
7 484 |
7 094 |
Payables and prepayments |
3 055 |
4 004 |
3 978 |
Government grants |
- |
152 |
- |
Total current liabilities |
4 505 |
11 640 |
11 073 |
|
|
|
|
Interest-bearing liabilities |
15 585 |
16 523 |
17 725 |
Payables and prepayments |
- |
- |
204 |
Deferred tax liabilities |
1 645 |
1 536 |
1 599 |
Government grants |
321 |
226 |
265 |
Total non-current liabilities |
17 551 |
18 285 |
19 792 |
TOTAL LIABILITIES |
22 056 |
29 925 |
30 865 |
|
|
|
|
Share capital |
7 737 |
7 737 |
7 737 |
Share premium |
14 007 |
14 007 |
14 007 |
Treasury shares |
- 390 |
- 390 |
- 390 |
Statutory capital reserve |
51 |
51 |
51 |
Currency translation differences |
261 |
815 |
839 |
Retained profit (loss) |
- 14 162 |
- 11 819 |
- 14 391 |
Equity attributable to parent |
7 504 |
10 401 |
7 853 |
Non-controlling interest |
246 |
- 278 |
199 |
TOTAL EQUITY |
7 750 |
10 123 |
8 052 |
TOTAL EQUITY AND LIABILITIES |
29 806 |
40 048 |
38 917 |
Consolidated Statement of Profit or Loss And Other
Comprehensive Income
EUR '000 |
3Q 2022/2023 |
3Q 2021/2022 |
9m 2022/2023 |
9m 2021/2022 |
Revenue |
3 675 |
7 379 |
15 585 |
36 878 |
Cost of goods sold |
-2 619 |
-7 698 |
-12 404 |
-34 270 |
Gross profit |
1 056 |
-319 |
3 181 |
2 608 |
|
|
|
|
|
Operating expenses |
-1 362 |
-1 149 |
-3 855 |
-5 853 |
Selling and distribution expenses |
-621 |
-964 |
- 1 935 |
-4 213 |
Administrative expenses |
-741 |
-185 |
-1 920 |
-1 640 |
Other income / expense |
66 |
-198 |
-2 |
-136 |
Fair value adjustment on biological assets |
170 |
246 |
0 |
314 |
Operating profit (loss) |
-71 |
-1 420 |
-677 |
-3 067 |
Financial income / expenses |
171 |
-3 283 |
1 619 |
-3 651 |
Profit (Loss) before tax |
101 |
-4 703 |
942 |
-6 718 |
Income tax |
2 |
192 |
-106 |
83 |
Net profit (loss) for the period |
103 |
-4 511 |
836 |
-6 635 |
|
|
|
|
|
Net profit (loss) attributable to: |
|
|
|
|
Owners of the Parent Company |
153 |
-4 481 |
821 |
-6 641 |
Non-controlling interests |
-51 |
-30 |
15 |
6 |
Total net profit (loss) for the period |
102 |
-4 511 |
836 |
-6 635 |
|
|
|
|
|
Other comprehensive income (loss) that may subsequently be
classified to profit or loss: |
|
|
|
|
Foreign currency translation differences |
-133 |
-140 |
-578 |
132 |
Total comprehensive income (expense) |
-31 |
-4 651 |
258 |
-6 503 |
|
|
|
|
|
Total comprehensive income (expense) attributable to: |
|
|
|
|
Owners of the Parent Company |
20 |
-4 621 |
243 |
-6 509 |
Non-controlling interests |
-51 |
-30 |
15 |
6 |
Total comprehensive income (expense) for the
period |
-31 |
-4 651 |
258 |
-6 503 |
|
|
|
|
|
Profit (Loss) per share (EUR) |
0.00 |
-0.12 |
0.02 |
-0.17 |
|
|
|
|
|
Diluted profit (loss) per share (EUR) |
0.00 |
-0.10 |
0.02 |
-0.15 |
Indrek Kasela
AS PRFoods
Member of the Management Board
Phone:+372 452 1470
investor@prfoods.ee
www.prfoods.ee
- PRF_interim_9m2022_2023 .docx
Prfoods As (LSE:0MOK)
Historical Stock Chart
From Nov 2024 to Dec 2024
Prfoods As (LSE:0MOK)
Historical Stock Chart
From Dec 2023 to Dec 2024